Press Release
Lund, Sweden, January 31, 2024

ImmuneBiotech, a pioneering probiotic and microbiome company, is pleased to announce the appointment of Dr. Sara Malcus as Chairman of the Board of Directors and Mr. Svante Hjertén as Member of the Board of Directors. These appointments mark a significant step in ImmuneBiotech’s development.

Dr. Malcus brings many years of experience from executive positions in both food and drug developing companies. Her deep understanding of the microbiome field aligns with ImmuneBiotech’s mission and will be valuable in shaping the company’s strategic direction and future growth.

“We are delighted to welcome Dr. Sara Malcus as Chairman of the Board,” says Shahram Lavasani, founder and CEO of ImmuneBiotech. “Her strong background in the microbiome and pharmaceutical industries, coupled with her extensive network in both industry and academia, will have a substantial impact on our strategy and future product development.”

Dr. Malcus’s appointment underscores ImmuneBiotech’s ongoing commitment to expanding its capabilities and fostering innovation in the probiotics and microbiome sector. This reaffirms the company’s dedication to delivering high quality products and services to its customers.

“I am excited to join ImmuneBiotech. The company’s commitment to innovation and human health aligns with my passion for transformative solutions in the life science industry. I look forward to contributing to ImmuneBiotech’s success, making a meaningful impact on the future of probiotics and microbiome development”, says Sara Malcus.

Joining Dr. Malcus on the Board is Mr. Svante Hjertén, attorney at law with a rich background in business law, corporate governance, and diverse board assignments across various industries. His extensive experience will contribute with valuable perspectives to ImmuneBiotech’s governance and strategic initiatives.

“We are very pleased to welcome Mr. Svante Hjertén to our Board,” Shahram continues. “His proficiency in business law and multifaceted leadership roles make him a valuable addition. We believe that his contribution will complement the strengths of our existing Board Members, further enhancing the governance structure of ImmuneBiotech.”

“I look forward to joining the company’s board, and contributing with new perspectives based on my experiences as a business lawyer and manager across diverse industries”, says Svante Hjertén.


About ImmuneBiotech AB

ImmuneBiotech Medical Sweden AB stands at the forefront of the probiotic and microbiome sector, committed to enhancing human health and wellbeing with cutting-edge solutions.

The company is developing and marketing precision-designed probiotic products, specifically targeting gastrointestinal and neurological conditions. Leveraging two decades of groundbreaking research, ImmuneBiotech has gained profound insights into the intricate interplay among the microbiome, immune system, and intestinal barrier, leading to the creation of the innovative probiotic category, ImmuneBiotics®.
With an unwavering commitment to excellence, research, and customer satisfaction, ImmuneBiotech aims to lead the rapidly evolving probiotics and microbiome industry.


GutMagnific®: Precision Probiotic Revolutionizing Human Health

GutMagnific stands as the flagship product in the ImmuneBiotics range, representing the essence of Precision Probiotics. It is specifically created for the effective management of gastrointestinal conditions. This scientifically-developed, multi-strain, patented probiotic food/nutritional supplement is designed to foster a healthy balance among the microbiome, immune system, and intestinal barrier. Remarkably, beyond gastrointestinal wellness, GutMagnific has shown significant clinical efficacy in neurological conditions, thereby addressing gut-brain axis issues.

Undergoing rigorous evaluation in a randomized, blinded, placebo controlled clinical study in collaboration with Karolinska Institute in Stockholm, Sweden, GutMagnific has demonstrated significant relief from both neurological and IBS symptoms in patients with myalgic encephalomyelitis (ME) also known as chronic fatigue syndrome (CFS). GutMagnific’s potential extends to several critical and widespread conditions with high unmet medical needs, such as constipation, abdominal pain, antibiotic induced diarrhea, and Clostridium difficile infection. It is also effective in targeting symptoms related to leaky gut and small intestine bacterial overgrowth (SIBO).

The distinctive clinical and health benefits of GutMagnific underscore ImmuneBiotech’s robust R&D platform, which applies pharmaceutical principles to achieve multi-targeted effects.

GutMagnific is available for purchase through the company’s web-shop


For further information, please contact:

Shahram Lavasani, CEO

ImmuneBiotech Medical Sweden AB
+46 700 90 8946